Fibroblast growth factors (FGFs) are a large family of protein ligands that exert a wide range of biological effects in many organs/tissues by activating receptors (FGFRs) of the tyrosine kinase superfamily [1, 2] . They are crucial for embryonic development as well as for tissue maintenance and repair in the adult organism [3] . Based on these physiological functions it is not surprising that FGFR signaling is dysregulated in practically every malignancy that has been analyzed in this context [4] . The FGFR activation is common in different tumor types, but only <10% of all tumors sequenced carry FGFR aberrations, such as gene amplifications, mutations and rearrangements [5] . Most commonly affected (up to 32%) are specific tumor types such as urothelial, breast, endometrial and squamous cell lung cancer. The more frequent mechanism is the upregulation of FGFs to establish autocrine and paracrine loops [6] [7] [8] . This adds an additional layer of complexity, because the secreted factors also affect cells of the microenvironment while FGFs produced in the microenvironment may stimulate the cancer cells [9] .
of small molecule inhibitors [25] and offers information about the regulation of FGFRs especially by plasma membrane-embedded partner proteins that may act as coreceptors [26] . In hepatocellular carcinomas [23] , but also in some other malignancies [24] , upregulation of FGFR4 is coupled to secretion of FGF19 to form an autocrine loop and offers a promising therapeutic target-especially as FGFR4-specific targeting compounds have been developed and are already in clinical trials [24] . Dai et al. give a comprehensive overview of the development of FGFR inhibitors and their specificities in relation to their interaction with the FGFR kinase domains [25] . Czys reports in her review on melanomas that alterations in FGF-signaling are not driving the malignant process, but they do increase with tumor progression and contribute to more aggressive phenotypes and therapy resistance [22] . Consequently, targeting FGFRs is suggested for combination therapy [22] . Similar observations have been reported for other malignancies, such as colon cancer [27, 28] , mesothelioma [29] , and lung cancer [30] .
Of the reports on original data, two articles by Nanni et al. and Csanaky et al. contribute results on FGFR-dependent signaling and its biological impact on autophagy and differentiation in non-malignant in vitro cell models [31, 32] . FGFR variant expression and subcellular localization are essential for the observed biological effects that could impact carcinogenesis. For example, the expression of mesenchymal FGFR variants, such as the IIIc alternative splicing variant in epithelial tumor cells, may increase FGFR signaling via paracrine FGF ligand effects [33] . Szybowska et al. analyzed the impact of FGFR2 mutations on downstream signaling and feed-back loops [34] . Santolla et al. address the issue of tumor cell-microenvironment cross-talk, as they report on interaction with the G-protein estrogen receptor upregulating FGF2 in cancer associated fibroblasts that in turn impacts on the FGFR1 expressing breast cancer cells [35] .
More tumor type-specific aspects are taken up in four research articles. Celik-Selvi et al. studied members of the Sprouty protein family that are well-known to inhibit FGFR signaling but some show a tumor-promoting function in brain cancer [36] . Vlacic [38] . Sarcomas exhibit predominant FGFR1 expression that can be specifically blocked in vitro in human and canine cell models [39] . FGFR expression profiles and blocking capacity were identical and support future comparative research in both species. In this Special Issue, a preclinical study in vivo by Hanes et al. identified amplified FRS2 as the determinant of response to FGFR-inhibitors in high-grade metastatic dedifferentiated liposarcoma, thus paving the way for clinical trials with a pan-FGFR inhibitor that may be more potent to block FGFR signaling in this specific sarcoma subtype [40] .
In conclusion, the data presented in this Special Issue extends our knowledge on targeting FGFR signaling for cancer therapy to new compounds/strategies and to new tumor types. They also demonstrate the need for further translational research to decipher the complex role of FGFR signaling for improved targeting in different cancer subtypes. 
